STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Trump administration planning to reimburse doctors treating vaccine ‘injury’
A new generation of disability rights activists carry on Judy Heumann's legacy
DR Congo: Ebola-awareness campaigns conducted at schools in Bunia
Mental health is no joke - but I've turned it into a stand-up routine
Ebola: In the DRC's main epicenter, first treatment trials rekindle hope
